Literature DB >> 21782033

Antimicrobial peptides in the duodenum at the acute and convalescent stages in patients with diarrhea due to Vibrio cholerae O1 or enterotoxigenic Escherichia coli infection.

Tahmina Shirin1, Arman Rahman, Åke Danielsson, Taher Uddin, Taufiqur Rahman Bhuyian, Alaullah Sheikh, Syed Saleheen Qadri, Firdausi Qadri, Marie-Louise Hammarström.   

Abstract

Patients with acute watery diarrhea caused by Vibrio cholerae O1 or enterotoxigenic Escherichia coli (ETEC) were analyzed for innate immune factors produced by the epithelium during the disease process. Duodenal biopsies were obtained from study participants at the acute (day 2) and convalescent (day 21) stages of disease. Levels of α-defensin (HD-5 and -6), β-defensin (hBD-1-4), and cathelicidin (LL-37) mRNAs were determined by real-time qRT-PCR. hBD-2, HD-5, LL-37 peptides were analyzed in duodenal epithelium by immunomorphometry. Concentration of hBD-2 in stool was determined by ELISA. Specimens from healthy controls were also analyzed. hBD-2 mRNA levels were significantly increased at acute stage of diarrhea; hBD-2 peptide was detected in fecal specimens but barely in duodenal epithelium at acute stage. Immunomorphometry analysis showed that Paneth cells contain significantly higher amounts of HD-5 pre/propeptide at convalescence (P<0.01) and in healthy controls (P<0.001) compared to acute stage, LL-37 peptide levels also decreased at acute stage while mRNA levels remained unchanged. mRNA expression levels of the other antimicrobial peptides remained unchanged with higher levels of α-defensins than β-defensins. V. cholerae induced an innate immune response at the acute stage of disease characterized by increased expression of hBD-2, and continued expression of hBD-1, HD-5-6, and LL-37.
Copyright © 2011 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21782033     DOI: 10.1016/j.micinf.2011.06.014

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  11 in total

1.  Treatment with Entinostat Heals Experimental Cholera by Affecting Physical and Chemical Barrier Functions of Intestinal Epithelia.

Authors:  Protim Sarker; Atanu Banik; Roger Stromberg; Gudmundur H Gudmundsson; Rubhana Raqib; Birgitta Agerberth
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 2.  Immune responses to cholera in children.

Authors:  Daniel T Leung; Fahima Chowdhury; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Expert Rev Anti Infect Ther       Date:  2012-04       Impact factor: 5.091

3.  An Update on Cholera Immunity and Current and Future.

Authors:  Jan Holmgren
Journal:  Trop Med Infect Dis       Date:  2021-04-28

4.  Host Antimicrobial Peptides in Bacterial Homeostasis and Pathogenesis of Disease.

Authors:  Derek R Heimlich; Alistair Harrison; Kevin M Mason
Journal:  Antibiotics (Basel)       Date:  2014-12-01

5.  Circulating mucosal associated invariant T cells are activated in Vibrio cholerae O1 infection and associated with lipopolysaccharide antibody responses.

Authors:  Daniel T Leung; Taufiqur R Bhuiyan; Naoshin S Nishat; Mohammad Rubel Hoq; Amena Aktar; M Arifur Rahman; Taher Uddin; Ashraful I Khan; Fahima Chowdhury; Richelle C Charles; Jason B Harris; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  PLoS Negl Trop Dis       Date:  2014-08-21

6.  Induction of immunomodulatory miR-146a and miR-155 in small intestinal epithelium of Vibrio cholerae infected patients at acute stage of cholera.

Authors:  Aziz Bitar; Rituparna De; Silvia Melgar; Kyaw Min Aung; Arman Rahman; Firdausi Qadri; Sun Nyunt Wai; Tahmina Shirin; Marie-Louise Hammarström
Journal:  PLoS One       Date:  2017-03-20       Impact factor: 3.240

Review 7.  Host Directed Therapy Against Infection by Boosting Innate Immunity.

Authors:  Peter Bergman; Rubhana Raqib; Rokeya Sultana Rekha; Birgitta Agerberth; Gudmundur H Gudmundsson
Journal:  Front Immunol       Date:  2020-06-12       Impact factor: 7.561

8.  Both group 4 capsule and lipopolysaccharide O-antigen contribute to enteropathogenic Escherichia coli resistance to human α-defensin 5.

Authors:  Jenny-Lee Thomassin; Mark J Lee; John R Brannon; Donald C Sheppard; Samantha Gruenheid; Hervé Le Moual
Journal:  PLoS One       Date:  2013-12-04       Impact factor: 3.240

9.  Anti-microbial peptide gene expression during oral vaccination: analysis of a randomized controlled trial.

Authors:  M Simuyandi; M Kapulu; P Kelly
Journal:  Clin Exp Immunol       Date:  2016-08-29       Impact factor: 4.330

Review 10.  Resistance to Antimicrobial Peptides in Vibrios.

Authors:  Delphine Destoumieux-Garzón; Marylise Duperthuy; Audrey Sophie Vanhove; Paulina Schmitt; Sun Nyunt Wai
Journal:  Antibiotics (Basel)       Date:  2014-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.